Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives $18.30 Consensus Price Target from Brokerages
Terns Pharmaceuticals, Inc. (NASDAQ:TERN – Get Free Report) has received an average rating of “Moderate Buy” from the six brokerages that are currently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price objective among […]
Terns Pharmaceuticals, Inc. (NASDAQ:TERN – Get Free Report) has received an average rating of “Moderate Buy” from the six brokerages that are currently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price objective among […]
